
Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma
Combining belantamab mafodotin-blmf (Blenrep) with dexamethasone and bortezomib (Velcade; BVd) demonstrated clinically meaningful and statistically significant improvements in outcomes like overall survival (OS) and progression-free survival (PFS) among …